Skip to content

MDMA research published in 2020

66 studies whose primary subject is MDMA were published in 2020, down from 71 in 2019. Newest first. Back to the MDMA overview

Studies

A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

Journal of Psychopharmacology December 20, 2020 Benjamin Illingworth, Declan J Lewis, Andrew T Lambarth et al. 47 citations

Rationale: Novel, evidence-based treatments are required for treatment-resistant post-traumatic stress disorder (PTSD). 3,4-Methylenedioxymethamphetamine (MDMA) has beneficially augmented psychotherapy in several small clinical trials. Objective: To review the use of MDMA-assisted psychotherapy in treatment-resistant PTSD. Methods: Systematic searches of four databases were conducted from...

DOI: 10.1177/0269881120965915 (opens in new tab) MDMA Placebo Meta-analysis Randomized controlled trial +3

Novel Psychoactive Phenethylamines: Impact on Genetic Material.

International Journal of Molecular Sciences December 17, 2020 Veronica Cocchi, Sofia Gasperini, Patrizia Hrelia et al. 32 citations

Psychedelic and stimulating phenethylamines belong to the family of new psychoactive substances (NPS). The acute toxicity framework has begun to be investigated, while studies showing genotoxic potential are very limited or not available. Therefore, in order to fill this gap, the aim of the present work was to evaluate the genotoxicity by treating TK6 cells with 2C-H, 2C-I, 2C-B, 25B-NBOMe, and...

MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial.

European Journal of Psychotraumatology December 7, 2020 Candice M Monson, Anne C Wagner, Ann T Mithoefer et al. 90 citations

Cognitive-behavioural conjoint therapy (CBCT) for PTSD has been shown to improve PTSD, relationship adjustment, and the health and well-being of partners. MDMA (3,4-methylenedioxymethamphetamine) has been used to facilitate an individual therapy for PTSD. This study was an initial test of the safety, tolerability, and efficacy of MDMA-facilitated CBCT. Six couples with varying levels of...

DOI: 10.1080/20008198.2020.1840123 (opens in new tab) Full text (opens in new tab) Cognitive-behavioural Conjoint Couple MDMA-Assisted Therapy MDMA +14

CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?

Intensive Care Medicine Experimental December 1, 2020 Patrick M. Honore, Sebastien Redant, Thomas Datzmann 2 citations

Abstract Background 3,4-Methylenedioxymethamphetamine intoxication can result in potentially lethal multi-organ failure, for which the current treatment is largely supportive. Recently, a report of the use of the CytoSorb device as a part of the successful treatment of a patient with 3,4-methylenedioxymethamphetamine intoxication and multi-organ failure has been described. Main body While...

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Journal of Neuroscience November 30, 2020 Danilo de Gregorio, Argel Aguilar-Valles, Katrin H. Preller et al. 258 citations

A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of...

Ecstasy (MDMA): A rebellion coherent with the system.

Nordisk Alkohol Nark November 28, 2020 José Manuel García-montes, Marino Pérez-Álvarez, Miguel Ángel Sánchez-Moya et al. 5 citations

Aim: This study attempts to demonstrate the relevance of the socio-cultural model of drugs in explaining the impressive development of ecstasy in the last 45 years. Method: First the study describes the use of ecstasy by groups which have left their imprint on the substance: university students, gays, yuppies and the "New Age" movement. Then the link between ecstasy and techno music led to the...

Increased response to 3,4 methylenedioxymethamphetamine (MDMA) reward and altered gene expression in zebrafish during short- and long-term nicotine withdrawal

Molecular Neurobiology November 24, 2020 Luisa Ponzoni, M. Teh, J. V. Torres-Pérez et al.

An interactive effect between nicotine and 3,4-methylenedioxymethamphetamine (MDMA) has been reported but the mechanism underlying such interaction is not completely understood. This study used zebrafish to explore gene expression changes associated with altered sensitivity to the rewarding effects of MDMA following 2-week exposure to nicotine and 2–60 days of nicotine withdrawal. Reward...

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study

Scientific Reports November 24, 2020 Julane Andries, Lisa Jerome, Evan Sola et al. 170 citations

Abstract The success of modern medicine creates a growing population of those suffering from life-threatening illnesses (LTI) who often experience anxiety, depression, and existential distress. We present a novel approach; investigating MDMA-assisted psychotherapy for the treatment of anxiety in people with an LTI. Participants with anxiety from an LTI were randomized in a double-blind study to...

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology November 21, 2020 Allison A. Feduccia, Lisa Jerome, Michael C Mithoefer et al. 39 citations Retracted

Abstract Rationale MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Objectives Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of...

MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens

Neuropsychopharmacology November 20, 2020 Felix Müller, Friederike Holze, Patrick C. Dolder et al. 43 citations

Abstract It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of hallucinogens and it was speculated that these shifts in connectivity underlie the characteristic subjective drug effects. In this study, we...

Zinc Protects against MDMA-Induced Apoptosis of Sertoli Cells in Mouse via Attenuation of Caspase-3

International Journal of Fertility and Sterility November 9, 2020 Nadia Hossein-Zadeh, Morteza Bagheri, Isa Abdi Rad et al.

Background: 3,4-Methylenedioxymethamphetamine (MDMA) disrupts function of the endocrine system and differentorgans such as heart, blood vessels, kidney, liver and nervous systems. This study was conducted to evaluateimpact of MDMA on apoptosis and Zinc in the MDMA-induced apoptosis of cultured Sertoli cells by measuringCaspase-3 gene expression.Materials and Methods: In this experimental study,...

From ecstasy to divine somnambulism: Henri Delacroix's studies in the history and psychology of mysticism.

History of psychology November 1, 2020 Matei Iagher

This article aims at placing Henri Delacroix's (1908) book on the psychology of mysticism in the context of debates in the psychology of religion in the earlier part of the 20th century. I argue that Delacroix's work was authored as part of a wider debate that Delacroix maintained with the American school of the psychology of religion regarding the role of emotions in religious experience. As I...

MDMA Use by Paris Medical Students: Prevalence and Characteristics

Substance Use & Misuse October 24, 2020 Balthazar Bazin, David Duroy, Michel Lejoyeux 27 citations

3,4-Methylenedioxy-N-methylamphetamine (MDMA) is increasing being used by youth in Europe and in France, but characteristics of its use are unknown. Objectives: The aim was to characterize MDMA use in a sample of French medical students. Methods: Cross-sectional study of Paris VII medical students (N = 592) with an online self-reporting questionnaire. Results: 592 students completed the online...

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

PLoS One October 14, 2020 Elliot Marseille, J. Kahn, B. Yazar-Klosinski et al. 55 citations

Background Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phase 2 trials. Its cost-effectiveness is unknown. Methods and findings To assess the...

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Journal of Psychopharmacology October 8, 2020 Yasmin Schmid, Peter Gasser, Peter Oehen et al. 82 citations

Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...

Methylenedioxymethamphetamine (MDMA)a.k.a. Ecstasy

Our Love Affair with Drugs October 1, 2020 Jerrold C Winter

Abstract As these words are written, the chemical we will call MDMA is a Schedule I drug. This means that MDMA (a) has no currently accepted medical use, (b) no currently accepted safety even under medical supervision, and (c) has a high potential for abuse. On the other hand, there are those who see great therapeutic potential in MDMA, and the Food and Drug Administration (FDA) has designated...

Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.

Farmacja Polska September 28, 2020 Agata Tadeja 1 citation

Research on using drugs in medicine was almost completely stopped and delegalized in 1971, by Convention on Psychotropic Substances. Most of studies carried out before 1971 were methodologically inappropriate according to current research methodologies, yet it was proven that there is some potential in using substances like lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine,...

The emerging role of psilocybin and MDMA in the treatment of mental illness

Expert Review of Neurotherapeutics September 21, 2020 Hartej Gill, Barjot Gill, David C J Chen-Li et al. 62 citations

Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety,...

Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin

Journal of Psychoactive Drugs September 15, 2020 Tracey Varker, Loretta Watson, Kari Gibson et al. 57 citations

The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the...

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy

Journal of Psychopharmacology September 10, 2020 H. Oeri 42 citations

The last two decades have seen a revival of interest in the entactogen 3,4-methylenedioxy-N-methylamphetamine (MDMA) as an adjunct to psychotherapy, particularly for the treatment of post-traumatic stress disorder. While clinical results are highly promising, and MDMA is expected to be approved as a treatment in the near future, it is currently the only compound in its class of action that is...